A complete application in a minute — tailored resume and cover letter, ready to send.
Slate Medicines is seeking a Director, CMC Quality to build and lead the biologics QA function from the ground up in a fast-paced startup environment. You will architect a phase-appropriate QMS and personally oversee audits, inspections, and regulatory interactions as the program advances from nonclinical to clinical stages.
The role requires 15+ years of biotech QA experience, hands-on QMS setup, and strong GMP knowledge, with a track record of regulatory inspections and cross-functional
*Direct applicants only. We are not working with third-party agencies.
Slate Medicines is a clinical-stage biotech company developing next-generation therapeutics for migraine and other headache disorders. Its lead program, SLTE-1009, is a subcutaneous monoclonal antibody targeting both PACAP and VIP, with the potential to be a best-in-class option for migraine prevention; the program entered Phase 1 in 2026, with topline data expected in mid-2027 and a Phase 2 start planned for 2027.
Slate is backed by leading healthcare investors including RA Capital Management, Forbion, Foresite Capital, and Frazier Life Sciences, and is on track to become a publicly traded company (Nasdaq: SLTE) through a planned merger with Fulcrum Therapeutics.
Slate Medicines is seeking an experienced, hands-on Director, CMC Quality to build and lead the biologics Quality function from the ground up. This is a foundational role for a quality leader who thrives in a fast-paced, resource-conscious start-up and can operate across the full spectrum of GxP quality - as both strategic architect and hands-on practitioner who reviews documents, conducts audits, and hosts inspections personally.
Required
Preferred